TRex Bio is focused on decoding human tissue biology to create revolutionary therapeutics for inflammatory diseases. By leveraging advancements in functional genomics and sequencing technologies, the company is investigating immune processes in human tissues at an unprecedented level. Their discovery platform maps tissue regulatory T-cell (Treg) behavior to disease mechanisms, enabling the identification of novel therapeutic targets. The team, comprising experienced scientists and industry leaders, is dedicated to advancing breakthrough medicines that can transform treatments for inflammatory conditions. With expertise in immunobiology, drug discovery, and computational biology, TRex Bio is leading the way in tissue biology and immune system research.